Monday, 31 August 2026European Markets

FINATIS Stock Bearish By 27% In The Last 21 Sessions

Loading stream...

finatis sa (cac 40: fnts.pa), a food distribution company with interests in sports equipment and real estate, witnessed their stock significantly decline by 27.36% over 21 sessions from eur4.02 to eur2.92, with five consecutive losses taking place as the cac 40 fell 1% overall to eur7,331.73.

company overview

finatis was established in paris, france in 1971 and currently operates several prominent supermarket chains like monoprix and casino supermarkets across france and latin america. additionally, this french-based firm maintains an expansive sports equipment market presence through the go sport brand as well as real estate assets with private equity investments.

evaluation of financial health

however, to further evaluate finatis' financial health, its twelve-month earnings per share (eps) stood at eur-24.26 - which represents its profitability - an indication of serious financial turbulence at finatis. for potential investors considering any equity investments with finatis amidst volatile finances and declining stock prices, these economic metrics indicate the need for extensive due diligence and risk assessment before considering making any decisions regarding equity purchases in this company. in an environment characterized by financial turmoil and decreasing stock prices, any decisions must be carefully planned out to minimize losses and ensure success.

more news about finatis (fnts.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com